In 2012, the growth rate of import and export of biochemical drugs slowed down

Source: China Pharmaceutical News, April 19, 2013, with the government's policy of supporting the pharmaceutical industry coming out one after another, the optimization and adjustment of the drug bidding model, the foundation and stability of the domestic economy, and the increasingly close relationship between domestic biochemical pharmaceutical enterprises and the international pharmaceutical industry, 2012 In, China's import and export of biochemical drugs still maintained a large and steady growth, but the growth rate slightly slowed down compared with the last two years In 2012, China's total import and export of biochemical drugs reached US $5.002 billion, an increase of 15.15% over the previous year Import: the trade deficit is still large Due to the steady growth of domestic economy, the recovery of market demand, the continuous enhancement of residents' medical expenditure capacity, and the technical advantages of biomedical products in developed countries, the import of biochemical drugs in China maintained a rapid growth momentum in 2012, with the import volume reaching US $2.743 billion, an increase of 34.18% year on year In 2012, there were 1119 enterprises engaged in the import of biochemical drugs in China, 159 enterprises with an import value of more than US $1 million, including Shanghai Roche Pharmaceutical Co., Ltd., Roche diagnostic products (Shanghai) Co., Ltd and Abbott Trading (Shanghai) Co., Ltd., Yongyu (Shanghai) Pharmaceutical Logistics Operation Co., Ltd., Keyuan Xinhai (Beijing) medical supplies Trading Co., Ltd., Shanghai Guoyao Waigaoqiao Pharmaceutical Co., Ltd., Baite medical supplies Trading (Shanghai) Co., Ltd., China animal husbandry industry and Commerce (Group) Corporation, Shenzhen Sanofi Pasteur biological products Co., Ltd., Liaoning Huiming International Trade Co., Ltd Ltd ranked in the top 10 biochemical drugs imports in that year, accounting for 54.52% In 2012, China imported biochemical drugs from 57 countries and regions, and Europe and North America are still the main import markets The top 10 trading partners of biochemical drugs import in China are the United States, Germany, Switzerland, France, Ireland, Austria, New Zealand, Denmark, Spain and Japan, with the top 10 accounting for 89.03% of the total import market, all of which are developed countries, with obvious market monopoly characteristics and large trade deficit This is mainly due to the late start of biomedical industry in developing countries, including China Compared with developed countries, both upstream technology and downstream technology in the industrial chain are obviously backward In 2012, China imported enzyme and coenzyme biochemical drugs reached US $180 million, up 7.71% year on year The import of human vaccine was US $155 million, down 18.2% year on year Shenzhen Sanofi Pasteur Biological Products Co., Ltd ranks first in the import volume of human vaccine, accounting for 47.90% of the total The company is mainly engaged in the sub packaging of imported biomedical products, and its main varieties include Haemophilus influenzae type B combined vaccine, group A Meningococcal polysaccharide vaccine, purified rabies vaccine for human use (Vero cell), polio inactivated vaccine, hepatitis A inactivated vaccine, influenza virus split vaccine, etc The import value of commodities under Tariff No 3002100090 "other antiserum, other blood and immune products" is USD 1.937 billion, accounting for 70.6% There are 346 enterprises engaged in the import of such commodities in China, among which Shanghai Roche Pharmaceutical Co., Ltd., Roche diagnostic products (Shanghai) Co., Ltd., Abbott Trading (Shanghai) Co., Ltd., Yongyu (Shanghai) Pharmaceutical Logistics Operation Co., Ltd and Baite medical products trading (Shanghai) Co., Ltd ranked the top 5 in the import volume of such commodities in 2012, accounting for a large proportion 52.84% Roche imported biomedical products mainly include trastuzumab for injection (Herceptin) and bevacizumab for injection (avidin) Herceptin's global sales reached 4.17 billion US dollars in 2010, and its patent will expire in 2019; avidin's global sales reached 5.54 billion US dollars in 2010, and its patent will also expire in 2019 Abbott Trading (Shanghai) Co., Ltd imports mainly adamumumab injection (sumac) Its global sales reached US $5.98 billion in 2010, and the patent will expire in 2018 Export: there was a slight negative growth year on year In 2012, the export volume of biochemical drugs in China was US $2.258 billion, down 1.78% year on year The main reasons for the year-on-year decline in export volume are as follows: the global economic downturn has led to tight monetary policy, lower willingness to purchase and insufficient power to replenish inventory, which has led to a decrease in the demand for drugs in foreign markets; the international competitiveness of domestic biochemical drugs is insufficient; the price of heparin products has fallen after years of favorable development and blowout in export trade In 2012, the export volume of heparin and its salt products was US $747 million, down 22.12% year on year In 2012, there were 1028 enterprises engaged in the export trade of biochemical drugs in China, 20 enterprises with an export value of more than US $1 million, including Shenzhen hiprui Pharmaceutical Co., Ltd., Nanjing Jianyou biochemical products Co., Ltd and Angel yeast Ltd., Yantai Dongcheng Biochemical Co., Ltd., Aibo biomedical (Hangzhou) Co., Ltd., Linyi Shansong Biological Products Co., Ltd., Shandong Gushen import and Export Co., Ltd., novozyme (China) Biotechnology Co., Ltd., Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd and Suzhou Hongda enzyme Manufacturing Co., Ltd ranked the top 10 in the export volume of biochemical drugs in China in 2012 In 2012, China's biochemical drugs were exported to 179 countries and regions, with an export volume of 835 million US dollars to Europe, down 13.86% year on year Europe's main export market accounts for 36.98% Exports to Asia amounted to US $680 million, an increase of 30.13% year on year In 2012, China's top 10 trade partners in biochemical drug export were the United States, France, Germany, Japan, Russia, India, Austria, South Korea, Italy and Brazil, accounting for 63.5% of the total Among them, the U.S market accounts for 20.25% and the export volume is 457 million US dollars The three largest export enterprises to the United States are Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Suzhou Hongda enzyme Manufacturing Co., Ltd and Aibo biological medicine (Hangzhou) Co., Ltd In 2012, heparin and its salt products were still the heavyweight export products of biochemical drugs in China, with an export volume of 747 million US dollars, accounting for 33.1% of the total The two enterprises with the largest export volume are Shenzhen hiprui Pharmaceutical Co., Ltd and Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., accounting for 53.37% of the export market of heparin products in China The export volume of enzyme and coenzyme biological drugs is US $281 million, accounting for 12.44% of the export volume of biochemical drugs in China The export value of human vaccine was 22.196 million US dollars, accounting for 0.98% The export volume of commodities under the item of "other antiserum, other blood and immune products" with tariff no of 3002100090 is US $173 million, accounting for 7.68% of the total export of biochemical drugs, which are exported to 140 countries and regions The main export markets are the United States, Turkey, France, Germany and India, accounting for 53.23% Among them, the United States accounts for 27.17% There are 147 enterprises operating the export of such commodities Among them, the export amount of Aibo biomedical (Hangzhou) Co., Ltd ranked first, reaching US $76.65 million, accounting for 44.21% of the total export amount of the product According to the statistics of the Ministry of industry and information technology, the total output value of China's pharmaceutical industry in 2012 was 1814.79 billion yuan The total output value of biomedical industry reached 185.27 billion yuan, a year-on-year increase of 20.5%; the operating revenue reached 177.54 billion yuan, a year-on-year increase of 18.8%; the total profit was 23.01 billion yuan, a year-on-year increase of 14.3% The proportion of biomedical industry in the overall pharmaceutical industry is 10.2%, which is still at a low level compared with the proportion of biomedical industry in developed countries, indicating that there is still a very large space for the development of China's biomedical industry In recent years, the government's support for biomedical industry has been increasing In the 12th Five Year Plan for the development of health services issued on October 19, 2012, biotechnology has been listed as one of the seven strategic emerging industries, and special funds for development will be set up to establish a stable financial investment growth mechanism and support the industrialization of innovation results; on August 3, 2012, the Ministry of Finance issued 2012 In, the proposed supporting units for the development of protein biopharmaceuticals and vaccines supported the supporting links of the development of the biopharmaceutical industry with special funds, with a total of 27 projects to be supported, focusing on the basic research and development of protein biopharmaceuticals and vaccine related products; 1, 2012 In June, the former Ministry of Health issued detailed rules to encourage the establishment of new plasma stations, which improved the collection of plasma collected by single collection, greatly increased the supply of blood products, and solved the problem of shortage of raw materials The new version of the national basic drug catalog recently released expanded the capacity of basic drug varieties from 307 to 520, including about 317 chemical and biological products The government's supporting policies will certainly inject huge momentum into the industry, promote the production and research and development of biochemical products, shorten the gap with developed countries in technology, and enhance the market development ability and international competitiveness of enterprises It can be predicted that with the support of national policies, the import and export trade of biochemical drugs in China will have a bright future in 2013 (data source: China Customs statistics collected by medical insurance chamber of Commerce)